This paper discusses the need for better treatment options for patients suffering from astrocytoma and glioblastoma (GBM), the two most frequently diagnosed primary brain tumors. In addition, secondary brain cancers that originate from the metastatic spread of peripheral cancers, such as those of the lung, skin, breast, kidneys, and gastrointestinal tract are about 10-fold more […]
Publication Date: February 19, 2025 Published By: New York Business Journal Article Link: https://www.bizjournals.com/newyork/news/2025/02/19/expanding-horizons-neonc-technologies-bold-vision.html NeOnc Executive Team: (l-r) Patrick Walters, Dr. Thomas Chen, Amir F. Heshmatpour, Keithly A. Garnett The biotechnology industry is influencing advancements in medicine, agriculture, environmental science, and industrial processes. With its potential to transform human health and address critical global challenges, […]
Dr. Chen during glioblastoma neurosurgery procedure at UCLA. In a gripping new episode of New Frontiers by Planet TV Studios, viewers are taken inside the revolutionary world of NeOnc Technologies Holdings, Inc., a biotech company redefining the battle against aggressive brain cancers. At the heart of this transformation is Dr. Thomas Chen, Director of […]
Publication Date: February 5, 2025 Published By: The Bio Report Podcast Article Link: https://open.spotify.com/episode/0raRIZm6OicjYXtrZSLdq9 NeOnc’s CEO and CSO Dr. Thomas Chen sat down for an interview on the Bio Report Podcast. The Bio Report podcast, hosted by award-winning journalist Daniel Levine, focuses on the intersection of biotechnology with business, science, and policy. “One of the […]
Publication Date: February 5, 2025 Published By: Progress, Potential, and Possibilities Podcast Article Link: https://www.progresspotentialpossibilities.com/podcast/episode/7d758fde/dr-thomas-chen-md-phd-ceocso-neonc-technologies-revolutionizing-the-fight-against-brain-cancers Dr. Thomas Chen, MD, Ph.D. is Founder, CEO & CSO, and Board Director, of NeOnc Technologies ( https://neonc.com/ ), a developer of a proprietary, patented platform technology that can potentially transport pharma-based therapeutics directly to the brain without the normal boundary restrictions […]
